Cognitive outcomes in prostate cancer treatment: insights from the ODENZA trial and future considerations

Bryan J Neth¹, Jeffrey S Wefel^{2

3}, Kevin T Nead^{3

4}

Affiliations

¹ Department of Neurology, Mayo Clinic, Rochester, MN, USA.
² Section of Neuropsychology, Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
³ Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁴ Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

PMID: 40376525
PMCID: PMC12076222
DOI: 10.21037/tau-2024-747

Editorial

Cognitive outcomes in prostate cancer treatment: insights from the ODENZA trial and future considerations

Bryan J Neth et al. Transl Androl Urol. 2025.

. 2025 Apr 30;14(4):864-867.

doi: 10.21037/tau-2024-747. Epub 2025 Apr 15.

Authors

Bryan J Neth¹, Jeffrey S Wefel^{2

3}, Kevin T Nead^{3

4}

Affiliations

¹ Department of Neurology, Mayo Clinic, Rochester, MN, USA.
² Section of Neuropsychology, Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
³ Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁴ Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

PMID: 40376525
PMCID: PMC12076222
DOI: 10.21037/tau-2024-747

No abstract available

Keywords: Prostate cancer; cognitive; second-generation androgen receptor antagonists; toxicity.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tau.amegroups.com/article/view/10.21037/tau-2024-747/coif). J.S.W. reports grants from Bayer, GT Medical Technologies, and Novocure; consulting fees from Intra-Cellular Therapies; and participation on a Data Safety Monitoring Board or Advisory Board for Bayer. K.T.N. is a CPRIT Scholar in Cancer Research. The other author has no conflicts of interest to declare.

Comment on

A Randomized, Open-label, Cross-over Phase 2 Trial of Darolutamide and Enzalutamide in Men with Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer: Patient Preference and Cognitive Function in ODENZA.
Colomba E, Jonas SF, Eymard JC, Delva R, Brachet PE, Neuzillet Y, Penel N, Roubaud G, Bompas E, Mahammedi H, Longo R, Helissey C, Barthélemy P, Borchiellini D, Hasbini A, Priou F, Saldana C, Voog E, Narcisso B, Ladoire S, Berdah JF, Aisenfarb JB, Foulon S, Fizazi K. Colomba E, et al. Eur Urol. 2024 Mar;85(3):274-282. doi: 10.1016/j.eururo.2023.05.009. Epub 2023 Jun 2. Eur Urol. 2024. PMID: 37271630 Clinical Trial.

References

1. Desai K, McManus JM, Sharifi N. Hormonal Therapy for Prostate Cancer. Endocr Rev 2021;42:354-73. 10.1210/endrev/bnab002 - DOI - PMC - PubMed
1. Schaeffer EM, Srinivas S, Adra N, et al. Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2023;21:1067-96. 10.6004/jnccn.2023.0050 - DOI - PubMed
1. Sumanasuriya S, De Bono J. Treatment of Advanced Prostate Cancer-A Review of Current Therapies and Future Promise. Cold Spring Harb Perspect Med 2018;8:a030635. 10.1101/cshperspect.a030635 - DOI - PMC - PubMed
1. Chen Y, Zhou Q, Hankey W, et al. Second generation androgen receptor antagonists and challenges in prostate cancer treatment. Cell Death Dis 2022;13:632. 10.1038/s41419-022-05084-1 - DOI - PMC - PubMed
1. Fizazi K, Shore N, Tammela TL, et al. Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer. N Engl J Med 2019;380:1235-46. 10.1056/NEJMoa1815671 - DOI - PubMed

Publication types

Actions
Actions

LinkOut - more resources

Full Text Sources
- AME Publishing Company
- PubMed Central

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Cognitive outcomes in prostate cancer treatment: insights from the ODENZA trial and future considerations

Affiliations

Cognitive outcomes in prostate cancer treatment: insights from the ODENZA trial and future considerations

Authors

Affiliations

Conflict of interest statement

Comment on

Similar articles

References

Publication types

LinkOut - more resources

Full Text Sources